ACM
PVLA

ADAR1 Capital Management’s Palvella Therapeutics PVLA Stock Holding History

ADAR1 Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-144,641
Closed -$1.74M – 256
2024
Q4 		$1.74M Hold
144,641
– – 0.35% 54
2024
Q3 		$2.4M Buy
+144,641
New +$2.11M 0.39% 44

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

ADAR1 Capital Management's PVLA Position: Q1 2025 in Review

ADAR1 Capital Management sold out of Palvella Therapeutics (PVLA) in Q1 2025, closing a stake of 144,641 shares — an estimated $1.74M sold.

ADAR1 Capital Management first reported a position in PVLA in Q3 2024 and held it in 2 quarters. The position peaked at $2.4M in Q3 2024. 41 funds tracked by Wall St. Rank hold PVLA as of Q1 2025.

  • ADAR1 Capital Management reported no remaining Palvella Therapeutics position as of Q1 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 144,641 Palvella Therapeutics shares in Q1 2025, an estimated $1.74M.
  • ADAR1 Capital Management first reported a position in Palvella Therapeutics in Q3 2024 and held it in 2 quarters.
  • ADAR1 Capital Management's Palvella Therapeutics position peaked at $2.4M in Q3 2024.
  • 41 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2025.

Based on ADAR1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.